Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease

Expert Opinion on Investigational Drugs

Volumn 14, Issue 6, 2005, Pages 729-738

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A2A antagonists; Dopamine; Dyskinesia; Istradefylline; Levodopa; Motor complications; Non dopaminergic; Parkinson's disease

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; LEVODOPA; NEW DRUG; PLACEBO; QUINPIROLE; UNCLASSIFIED DRUG; V 2006; VER 11135; VR 2006;

ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INFECTION; INSOMNIA; LOCOMOTION; MEDIASTINUM DISEASE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; RESPIRATORY TRACT DISEASE; THORAX DISEASE; VASCULAR DISEASE; VOMITING;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PARKINSON DISEASE; PURINES; RECEPTOR, ADENOSINE A2A;

EID: 21244440664     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.6.729     Document Type: Article

References (58)

1. McDONALD WM, RICHARD IH, DELONG MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol. Psychiatry (2003) 54(3):363-375.
2. SHASTRY BS: Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res. (2001) 41(1):5-12.
3. OLANOW CW, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology (1998) 50(3 Suppl. 3):S1-S57.
4. ROMRELL J, FERNANDEZ HH, OKUN MS: Rationale for current therapies in Parkinson's disease. Exp. Opin. Pharmacother. (2003) 4(10):1747-1761.
5. FOLTYNIE T, SAWCER S, BRAYNE C, BARKER RA: The genetic basis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (2002) 73(4):363-370.
6. WOOTEN GF, CURRIE LJ, BOVBJERG VE, LEE JK, PATRIE J: Are men at greater risk for Parkinson's disease than women? J. Neurol. Neurosurg. Psychiatry (2004) 75(4):637-639.
7. GUTTMAN M, KISH SJ, FURUKAWA Y: Current concepts in the diagnosis and management of Parkinson's disease. Can. Med. Assoc. J. (2003) 168(3):293-301.
8. SUCHOWERSKY O: Parkinson's disease: medical treatment of moderate to advanced disease. Curr. Neurol. Neurosci. Rep. (2002) 2(4):310-316.
9. SCHEIFE RT, SCHUMOCK GT, BURSTEIN A, GOTTWALD MD, LUER MS: Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am. J. Health. Syst. Pharm. (2000) 57(10):953-962.
10. DODEL RC, BERGER K, OERTEL WH: Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics (2001) 19(10):1013-1038.
11. KATZENSCHLAGER R, LEES AJ: Treatment of Parkinson's disease: levodopa as the first choice. J. Neurol. (2002) 249(Suppl. 2):II19-II24.
12. BONUCCELLI U: Comparing dopamine agonists in Parkinson's disease. Curr. Opin. Neurol. (2003) 16(Suppl. 1):S13-S19.
13. JENNER P: Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr. Opin. Neurol. (2003) 16(Suppl. 1):S3-S7.
14. RASCOL O, PAYOUX P, ORY F, FERREIRA JJ, BREFEL-COURBON C, MONTASTRUC JL: Limitations of current Parkinson's disease therapy. Ann. Neurol. (2003) 53(Suppl. 3):S3-S12.
15. OLANOW CW: The scientific basis for the current treatment of Parkinson's disease. Ann. Rev. Med. (2004) 55:41-60.
16. SANTENS P, BOON P, VAN ROOST D, CAEMAERT J: The pathophysiology of motor symptoms in Parkinson's disease. Acta Neurol. Belg. (2003) 103(3):129-134.
17. STOWE RL, WHEATLEY K, CLARKE CE et al.: Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J. Neurol. Neurosurg. Psychiatry (2003) 74(4):519-521.
18. FOLLETT KA: Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg. Focus (2004) 17(1):14-19.
19. 2A receptors in brain: morphological substrates for integration of striatal function. Neurology (2003) 61(11 Suppl. 6):S12-S18.
20. 2A antagonists. Neurology (2003) 61(11 Suppl. 6):S44-S48.
21. 2A receptor selective antagonist KW-6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology (2003) 61(11 Suppl. 6):S97-S100.
22. AGNATI LF, FERRE S, LLUIS C, FRANCO R, FUXE K: Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. (2003) 55(3):509-550.
23. 2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology (2003) 61(11 Suppl. 6):S19-S23.
24. FERRE S, POPOLI P, GIMENEZ-LLORT L et al.: Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. (2001) 7(3):235-241.
25. FERRE S, FREDHOLM BB, MORELLI M, POPOLI P, FUXE K: Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. (1997) 20(10):482-487.
26. FERRE S, O'CONNOR WT, FUXE K, UNGERSTEDT U: The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. (1993) 13(12):5402-5406.
27. FERRE S, FUXE K, VON EG, JOHANSSON B, FREDHOLM BB: Adenosine-dopamine interactions in the brain. Neuroscience (1992) 51(3):501-512.
28. 2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA (2002) 99(18):11940-11945.
29. 2A-receptor antagonists: beyond dopaminergic therapies for Parkinson's disease. Drug Discov. Today: Therapeutic Strategies (2004) 1(1):51-57.
30. 2A receptor antagonists. Farmaco (2001) 56(1-2):87-90.
31. 2A receptor knockout mice. Br. J. Pharmacol. (2001) 134(1):68-77.
32. 2A antagonist KW-6002 from animal models to parkinsonian patients. Neurology (2003) 61(11 Suppl. 6):S107-S111.
33. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. (1998) 43(4):507-513.
34. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. (2000) 162(2):321-327.
35. 2A receptor antagonists as neuroprotective agents. Curr. Med. Chem. Cent. Nerv. Syst. Agents (2004) 4(1):35-45.
36. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res. (2002) 953(1-2):119-125.
37. 2A receptors in rats. Synapse (2001) 42(3):164-176.
38. 11C]KW-6002 PET study in healthy subjects. Neurology (2005) 64(Suppl. 1):A235.
39. DATA ON FILE. Kyowa Pharmaceutical, Inc. Princeton, NJ, USA.
40. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl.) (1999) 147(1):90-95.
41. KWON M-O, FISCHER F, MATTHISSON M, HERRLING P: List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis. (2004) 1:113-152.
42. 2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J. Neurochem. (2003) 94(6):1398-1410.
43. 2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience (2004) 127(1):223-231.
44. 2A receptor antagonist. J. Neurosci. (2000) 20(15):5848-5852.
45. 2A receptor antagonist istradefylline in advanced PD. Neurology (2003) 61(3):297-303.
46. 2A receptor antagonist treatment of Parkinson's disease. Neurology (2003) 61(3):293-296.
47. HAUSER RA, FRIEDLANDER J, ZESIEWICZ TA et al.: A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. (2000) 23(2):75-81.
48. LEVIITT PA, THE 6002-US-005/6002-US-006 CLINICAL INVESTIGATOR GROUP: "OFF" time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patient with advanced Parkinson's disease (2004). Presented at Movement Disorder Society's 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy (June 13 - 17 2004).
49. STACY M, THE 6002-US-005/6002-US-006 CLINICAL INVESTIGATOR GROUP: Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: a positive safety profile with supporting efficacy (2004). Presented at Movement Disorder Society's 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy (June 13 - 17 2004).
50. 2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology (2003) 61(11 Suppl. 6):S74-S81.
51. 2A receptors in nonlocomotor features of Parkinson's disease: introduction. Neurology (2003) 61(11 Suppl. 6):S72-S73.
52. 2A receptors and depression. Neurology (2003) 61(11 Suppl. 6):S82-S87.
53. 2A receptor modulation. Neurology (2003) 61(11 Suppl. 6):S88-S93.
54. KOLLER WC, CERSOSIMO MG: Neuroprotection in Parkinson's disease: an elusive goal. Curr. Neurol. Neurosci. Rep. (2004) 4(4):277-283.
55. 2A receptor antagonists. Neurology (2003) 61(11 Suppl. 6):S62-S68.
56. LEWITT PA: Clinical trials of neuroprotection for Parkinson's disease. Neurology (2004) 63(7):S23-S31.
57. 2A receptor antagonists in animal models of Parkinson's disease. Neurology (2003) 61(11 Suppl. 6):S55-S61.
58. 2A receptors. Neurology (2003) 61(11 Suppl. 6):S69-S71.